NewAmsterdam Pharma N.V. (NAMS)
NASDAQ: NAMS
· Real-Time Price · USD
25.38
0.21 (0.83%)
At close: Aug 15, 2025, 1:29 PM
Company Description
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases.
Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C).
The company was founded in 2019 and is based in Naarden, the Netherlands.
NewAmsterdam Pharma N.V.
| Country | NL |
| IPO Date | Feb 9, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 68 |
| CEO | Michael Harvey Davidson FACC, Facp., |
Contact Details
Address: Gooimeer 2-35 Naarden, NL | |
| Website | https://www.newamsterdampharma.com |
Stock Details
| Ticker Symbol | NAMS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001936258 |
| CUSIP Number | n/a |
| ISIN Number | NL00150012L7 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | Chief Executive Officer, President, Executive Board Member & Director |
| Douglas F. Kling | Chief Operating Officer |
| Maryellen McQuade | Chief People Officer |
| Mayur Amrat Somaiya | Chief Financial Officer |
| Bob Rambo | Executive Vice President of Marketing |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director |
| Dr. Marc Ditmarsch M.D. | Chief Development Officer |
| Juliette Audet M.B.A., M.Sc. | Chief Strategy & Business Officer |
| Louise Kooij | Chief Accounting Officer |
| Matthew Philippe | Executive Vice President &Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | 4 | Filing |
| Aug 13, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Aug 12, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Aug 06, 2025 | 8-K | Current Report |
| Aug 06, 2025 | 10-Q | Quarterly Report |
| Jul 30, 2025 | 8-K | Current Report |
| Jul 17, 2025 | 4 | Filing |
| Jul 11, 2025 | 8-K | Current Report |
| Jun 26, 2025 | 4 | Filing |
| Jun 18, 2025 | 4 | Filing |